Oxygen Biotherapeutics Inc Stock Nasdaq
Equities
US69207P3082
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.27M 8.61M |
---|---|---|---|---|---|
Net income 2024 * | -19M -26.11M | Net income 2025 * | -18M -24.73M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.39
x | P/E ratio 2025 * |
-0.86
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 21-07-13 | |
Director of Finance/CFO | 69 | 01-10 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 21-01-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 14-04-03 |
June Almenoff
BRD | Director/Board Member | 67 | 21-02-24 |
Declan Doogan
BRD | Director/Board Member | 72 | 21-02-24 |
1st Jan change | Capi. | |
---|---|---|
+46.03% | 55.66B | |
-7.53% | 38.98B | |
+36.02% | 38.8B | |
-9.38% | 27.32B | |
+12.31% | 26.29B | |
-16.38% | 20.25B | |
+30.79% | 12.76B | |
+28.57% | 12.18B | |
-0.36% | 12.12B |